Doxorubicin resistant cancer cells activate myeloid-derived suppressor cells by releasing PGE2

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Rong, Yuan ^a   Yuan, Chun Hui ^a   Qu, Zhen ^a   Zhou, Hu ^a   Guan, Qing ^a   Yang, Na ^a   Leng, Xiao Hua ^b   Bu, Lang ^a   Wu, Ke ^a   Wang, Fu Bing ^a  

^a WUHAN UNIVERSITY   (China)

^b ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTAGOMIR; DOXORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA; MIRN10 MICRORNA, HUMAN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; RNA; TUMOR PROTEIN;

ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG RESISTANCE; GENETICS; HUMAN; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTAGOMIRS; CELL LINE, TUMOR; DINOPROSTONE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICRORNAS; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASM PROTEINS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA, NEOPLASM;

EID: 84962916640     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23824     Document Type: Article

References (64)

1. Ortiz, M. L., Lu, L., Ramachandran, I., Gabrilovich, D. I. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol Res 2, 50-58 (2014).
2. Marvel, D., Gabrilovich, D. I. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 1-9 (2015).
3. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 22, 238-244 (2010).
4. Boutte, A. M., McDonald, W. H., Shyr, Y., Yang, L., Lin, P. C. Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. Plos One 6, e22446 (2011).
5. Gabrilovich, D. I., Ostrand-Rosenberg, S., Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12, 253-268 (2012).
6. Ostrand-Rosenberg, S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59, 1593-1600 (2010).
7. Alizadeh, D. et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res 74, 104-118 (2014).
8. Acharyya, S. et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150, 165-178 (2012).
9. Bandyopadhyay, A. et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. Plos One 5, e10365 (2010).
10. Liu, Y. et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 188, 5500-5510 (2012).
11. Li, L. et al. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol 192, 1034-1043 (2014).
12. Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 517, 209-213 (2015).
13. Fujino, H., Salvi, S., Regan, J. W. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol Pharmacol 68, 251-259 (2005).
14. Kim, S. H. et al. Distinct protein kinase A anchoring proteins direct prostaglandin E2 modulation of Toll-like receptor signaling in alveolar macrophages. J Biol Chem 286, 8875-8883 (2011).
15. Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65, 3044-3048 (2005).
16. Talmadge, J. E. et al. Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. Int Immunopharmacol 7, 140-151 (2007).
17. O'Neill, L. A., Sheedy, F. J., McCoy, C. E. MicroRNAs: the fine-tuners of Toll-like receptor signalling. Nat Rev Immunol 11, 163-175 (2011).
18. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
19. Huang, X. et al. miR-620 promotes tumor radioresistance by targeting 15-hydroxyprostaglandin dehydrogenase (HPGD). Oncotarget 6, 22439-22451 (2015).
20. Krysan, K. et al. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res 12, 765-774 (2014).
21. Yan, Y. et al. miR-10a controls glioma migration and invasion through regulating epithelial-mesenchymal transition via EphA8. Febs Letters 589, 756-765 (2015).
22. Pogribny, I. P. et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer 127, 1785-1794 (2010).
23. Lund, A. H. miR-10 in development and cancer. Cell Death Differ 17, 209-214 (2010).
24. Hoppe, R. et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptorpositive breast cancer following tamoxifen treatment. Eur J Cance. 49, 3598-3608 (2013).
25. Riganti, C., Kopecka, J., Panada, E., Barak, S., Rubinstein, M. The role of C/EBP-beta LIP in multidrug resistance. J Natl Cancer Inst 107 (2015).
26. Bonhoure, E. et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 20, 95-102 (2006).
27. Talmadge, J. E., Gabrilovich, D. I. History of myeloid-derived suppressor cells. Nat Rev Cancer 13, 739-752 (2013).
28. Yang, W. C., Ma, G., Chen, S. H., Pan, P. Y. Polarization and reprogramming of myeloid-derived suppressor cells. J Mol Cell Biol 5, 207-209 (2013).
29. Eisenstein, S. et al. Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy. Cancer Res 73, 5003-5015 (2013).
30. Eruslanov, E., Daurkin, I., Ortiz, J., Vieweg, J., Kusmartsev, S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE(2) catabolism in myeloid cells. J Leukoc Biol 88, 839-848 (2010).
31. Eruslanov, E., Daurkin, I., Vieweg, J., Daaka, Y., Kusmartsev, S. Aberrant PGE(2) metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol 11, 848-855 (2011).
32. MacKenzie, K. F. et al. PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIKCRTC3 pathway. J Immunol 190, 565-577 (2013).
33. Frolov, A., Yang, L., Dong, H., Hammock, B. D., Crofford, L. J. Anti-inflammatory properties of prostaglandin E2: deletion of microsomal prostaglandin E synthase-1 exacerbates non-immune inflammatory arthritis in mice. Prostaglandins Leukot Essent Fatty Acids 89, 351-358 (2013).
34. Rogers, L. M. et al. EP4 and EP2 receptor activation of protein kinase A by prostaglandin E2 impairs macrophage phagocytosis of Clostridium sordellii. Am J Reprod Immunol 71, 34-43 (2014).
35. Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., Kalinski, P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 118, 5498-5505 (2011).
36. Condamine, T., Gabrilovich, D. I. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32, 19-25 (2011).
37. Hardie, D. G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8, 774-785 (2007).
38. Hammami, I. et al. Immunosuppressive activity enhances central carbon metabolism and bioenergetics in myeloid-derived suppressor cells in vitro models. Bmc Cell Biology 13, 18 (2012).
39. Zhu, Z. J. et al. Prostaglandin E2 Promotes Endothelial Differentiation from Bone Marrow-Derived Cells through AMPK Activation. Plos One 6, e23554 (2011).
40. Kalinski, P. Regulation of Immune Responses by Prostaglandin E-2. J Immunol 188, 21-28 (2012).
41. Xue, X. C. et al. Microbiota Downregulates Dendritic Cell Expression of miR-10a, Which Targets IL-12/IL-23p40. J Immunol 187, 5879-5886 (2011).
42. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58, 49-59 (2009).
43. Gallina, G. et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8(+ ) T cells. J Clin Invest 116, 2777-2790 (2006).
44. Lesokhin, A. M. et al. Monocytic CCR2(+ ) Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. Cancer Res 72, 876-886 (2012).
45. Grivennikov, S. I., Greten, F. R., Karin, M. Immunity, Inflammation, and Cancer. Cell 140, 883-899 (2010).
46. Moschella, F. et al. Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide. Cancer Res 71, 3528-3539 (2011).
47. Moschella, F. et al. Cyclophosphamide Induces a Type I Interferon-Associated Sterile Inflammatory Response Signature in Cancer Patients' Blood Cells: Implications for Cancer Chemoimmunotherapy. Clin Cancer Res 19, 4249-4261 (2013).
48. Fujita, M. et al. COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. Cancer Res 71, 2664-2674 (2011).
49. Veltman, J. D. et al. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. Bmc Cancer 10, 464 (2010).
50. Chen, C. Z., Li, L., Lodish, H. F., Bartel, D. P. MicroRNAs modulate hematopoietic lineage differentiation. Science 303, 83-86 (2004).
51. Liu, Q. F. et al. miR-223 suppresses differentiation of tumor-induced CD11b(+ )Gr1(+ )myeloid-derived suppressor cells from bone marrow cells. Int J Cancer 129, 2662-2673 (2011).
52. Zhang, M. M. et al. Both miR-17-5p and miR-20a Alleviate Suppressive Potential of Myeloid-Derived Suppressor Cells by Modulating STAT3 Expression. J Immunol 186, 4716-4724 (2011).
53. Li, L. M. et al. MicroRNA-155 and MicroRNA-21 Promote the Expansion of Functional Myeloid-Derived Suppressor Cells. J Immunol 192, 1034-1043 (2014).
54. Yan, Y. et al. MicroRNA-10a Is Involved in the Metastatic Process by Regulating Eph Tyrosine Kinase Receptor A4-Mediated Epithelial-Mesenchymal Transition and Adhesion in Hepatoma Cells. Hepatology 57, 667-677 (2013).
55. Sinha, P., Clements, V. K., Fulton, A. M., Ostrand-Rosenberg, S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res 67, 4507-4513 (2007).
56. Tilly, P. et al. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res 101, 482-491 (2014).
57. Chen, K. et al. Caloric Restriction Mimetic 2-Deoxyglucose Antagonizes Doxorubicin-induced Cardiomyocyte Death by Multiple Mechanisms. J Biol Chem 286, 21993-22006 (2011).
58. Tao, Z. M., Withers, H. G., Penefsky, H. S., Goodisman, J., Souid, A. K. Inhibition of cellular respiration by doxorubicin. Chem Res Toxicol 19, 1051-1058 (2006).
59. Kelly, M., Gauthier, M. S., Saha, A. K., Ruderman, N. B. Activation of AMP-Activated Protein Kinase by Interleukin-6 in Rat Skeletal Muscle Association With Changes in cAMP, Energy State, and Endogenous Fuel Mobilization. Diabetes 58, 1953-1960 (2009).
60. Wang, W., Guan, K. L. AMP-activated protein kinase and cancer. Acta Physiologica 196, 55-63 (2009).
61. Faour, W. H., Gomi, K., Kennedy, C. R. PGE(2) induces COX-2 expression in podocytes via the EP(4) receptor through a PKAindependent mechanism. Cell Signal 20, 2156-2164 (2008).
62. Xiang, X. et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 124, 2621-2633 (2009).
63. Feng, Y. H. et al. MicroRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med 29, 920-926 (2012).
64. Oliveras-Ferraros, C. et al. Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin Induction of the tumor suppressor miRNA let-7a and suppression of the TGF beta-induced oncomiR miRNA-181a. Cell Cycle 10, 1144-1151 (2011).